Abstract
TAVR specific risk assessment tools for one year mortality and morbidity are lacking. We evaluated 459 consecutive patients undergoing TAVR at our institution with balloon expandable valve. Data was collected using electronic medical record and imaging databases. Primary endpoint a composite of 12-
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.